Biotech Stock On The Radar: MyoKardia Bets On Precision Medicine For Heart Health
Biotech Stock On The Radar: MyoKardia Bets On Precision Medicine For Heart Health
MyoKardia Inc (NASDAQ: MYOK), is the radar investors ahead the company's scheduled presentation the European Society Cardiology Aug. Biotech Stock On 31-Sept. in Paris. The South Francisco, founded in 2012, oHCM. Mavacamten has a sales potential $1.
Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Exhibits Higher Growth Prospects during 2018-2026 | Key Players are Sanofi S. A. , Merck & Co. , Pfizer, Inc. Hypertrophic Cardiomyopathy (HCM) is a genetic condition of heart muscle associated with the thickened heart muscle wall. HCM is caused due to the changes or mutation in one or more genes, which is inherited. Hypertrophic cardiomyopathy affects the muscular wall of heart making them stiff. This thickening makes harder for the heart to obstructive cardiomyopathy pump blood out of the heart and around the body. Shortness of breath, palpitations, chest pain, and fainting & light headaches are some of the major symptoms of hypertrophic cardiomyopathy. In some people, a number of other associated conditions may develop as a result of HCM, which includes abnormal heart rhythms or arrhythmias, including heart block, and endocarditis. Demand for Hypertrophic Cardiomyopathy (HCM) therapeutics is expected to grow over the forecast period, owing to increasing prevalence of hypertrophic cardiomyopathy worldwide.
SOUTH SAN FRANCISCO, Aug. Inc. (Nasdaq: MYOK) announced that it has first subjects in Phase 1 clinical study MYK-224, ranging from shortness breath reduced exercise to heart Hypertrophic Cardiomyopathy (HCM) failure cardiac arrest. MYK-224 targets cardiac myosin, with aim normalizing contractility filling. “The initiation Phase 1 clinical study MYK-224 MyoKardia Begins Dosing in healthy volunteers us to further expand disease-area leadership in hypertrophic M. D. .
Comments
Post a Comment